Intermediate-term outcome of Aurolab aqueous drainage implant
Purpose: To report the intermediate-term safety and efficacy of Aurolab aqueous drainage implant (AADI) in patients with glaucoma. Methods: Retrospective review of patients who underwent AADI between January 2013 and December 2016. Patients aged >16 years and with a minimum follow-up of 6 months...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=2;spage=233;epage=238;aulast=Philip |
| _version_ | 1819025897509879808 |
|---|---|
| author | Reji Philip Premanand Chandran Nabeed Aboobacker Mrunali Dhavalikar Ganesh V Raman |
| author_facet | Reji Philip Premanand Chandran Nabeed Aboobacker Mrunali Dhavalikar Ganesh V Raman |
| author_sort | Reji Philip |
| collection | DOAJ |
| description | Purpose: To report the intermediate-term safety and efficacy of Aurolab aqueous drainage implant (AADI) in patients with glaucoma. Methods: Retrospective review of patients who underwent AADI between January 2013 and December 2016. Patients aged >16 years and with a minimum follow-up of 6 months were included. Success was defined as complete when the intraocular pressure was ≥6 and ≤21 mmHg without antiglaucoma medication and as qualified if those requiring additional antiglaucoma medications were included. Results: The study included 55 patients (55 eyes) with a mean age ± standard deviation (SD) of 47.3 ± 18.1 years with a mean follow-up of 16.7 ± 11.4 months. Mean intraocular pressure reduced from 30.8 ± 11.1 mmHg to 13.1 ± 4.7, 14.1 ± 4.8, 15.7 ± 2.5 (P < 0.001) mmHg at 6 months, 1 year, and 2 years, respectively. The mean number of antiglaucoma medications reduced from 3.4 ± 1 to 0.8 ± 1.2, 0.7 ± 1.1, 0.8 ± 1 (P < 0.001) at 6 months, 1 year, and 2 years, respectively. The cumulative probability of complete and qualified success was 62% and 100% at 6 months, 54% and 92% at 1 year, and 43% and 88% at 2 years, respectively. Four patients failed during the follow-up period. Postoperative complication occurred in 28 eyes (51%), of which 17 eyes (31%) required intervention. Conclusion: AADI is a safe and effective treatment for the control of intraocular pressure in patients with glaucoma. |
| first_indexed | 2024-12-21T05:17:59Z |
| format | Article |
| id | doaj.art-21c4d9afc1b34296b9fc24b109c4c3ca |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-12-21T05:17:59Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-21c4d9afc1b34296b9fc24b109c4c3ca2022-12-21T19:14:53ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892019-01-0167223323810.4103/ijo.IJO_675_18Intermediate-term outcome of Aurolab aqueous drainage implantReji PhilipPremanand ChandranNabeed AboobackerMrunali DhavalikarGanesh V RamanPurpose: To report the intermediate-term safety and efficacy of Aurolab aqueous drainage implant (AADI) in patients with glaucoma. Methods: Retrospective review of patients who underwent AADI between January 2013 and December 2016. Patients aged >16 years and with a minimum follow-up of 6 months were included. Success was defined as complete when the intraocular pressure was ≥6 and ≤21 mmHg without antiglaucoma medication and as qualified if those requiring additional antiglaucoma medications were included. Results: The study included 55 patients (55 eyes) with a mean age ± standard deviation (SD) of 47.3 ± 18.1 years with a mean follow-up of 16.7 ± 11.4 months. Mean intraocular pressure reduced from 30.8 ± 11.1 mmHg to 13.1 ± 4.7, 14.1 ± 4.8, 15.7 ± 2.5 (P < 0.001) mmHg at 6 months, 1 year, and 2 years, respectively. The mean number of antiglaucoma medications reduced from 3.4 ± 1 to 0.8 ± 1.2, 0.7 ± 1.1, 0.8 ± 1 (P < 0.001) at 6 months, 1 year, and 2 years, respectively. The cumulative probability of complete and qualified success was 62% and 100% at 6 months, 54% and 92% at 1 year, and 43% and 88% at 2 years, respectively. Four patients failed during the follow-up period. Postoperative complication occurred in 28 eyes (51%), of which 17 eyes (31%) required intervention. Conclusion: AADI is a safe and effective treatment for the control of intraocular pressure in patients with glaucoma.http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=2;spage=233;epage=238;aulast=PhilipAdult glaucomaAurolab aqueous drainage implantglaucoma drainage device |
| spellingShingle | Reji Philip Premanand Chandran Nabeed Aboobacker Mrunali Dhavalikar Ganesh V Raman Intermediate-term outcome of Aurolab aqueous drainage implant Indian Journal of Ophthalmology Adult glaucoma Aurolab aqueous drainage implant glaucoma drainage device |
| title | Intermediate-term outcome of Aurolab aqueous drainage implant |
| title_full | Intermediate-term outcome of Aurolab aqueous drainage implant |
| title_fullStr | Intermediate-term outcome of Aurolab aqueous drainage implant |
| title_full_unstemmed | Intermediate-term outcome of Aurolab aqueous drainage implant |
| title_short | Intermediate-term outcome of Aurolab aqueous drainage implant |
| title_sort | intermediate term outcome of aurolab aqueous drainage implant |
| topic | Adult glaucoma Aurolab aqueous drainage implant glaucoma drainage device |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=2;spage=233;epage=238;aulast=Philip |
| work_keys_str_mv | AT rejiphilip intermediatetermoutcomeofaurolabaqueousdrainageimplant AT premanandchandran intermediatetermoutcomeofaurolabaqueousdrainageimplant AT nabeedaboobacker intermediatetermoutcomeofaurolabaqueousdrainageimplant AT mrunalidhavalikar intermediatetermoutcomeofaurolabaqueousdrainageimplant AT ganeshvraman intermediatetermoutcomeofaurolabaqueousdrainageimplant |